Fermenta Biotech Q1 FY27: Capex ₹110 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹122Cr
- −10.6% YoY
- +0.2% QoQ
- Net profit
- ₹10Cr
- −55.9% YoY
- −48.8% QoQ
- Margin
- 14.83%
- −5.9 pp YoY
- −1.6 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Fermenta Biotech Ltd Q1 FY27 key numbers
- Revenue
- Revenue ex-real estate: INR 124.3 crore, down 12% YoY.
As stated in Fermenta Biotech Ltd's Q1 FY27 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Fermenta Biotech Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1FY27 total revenue: INR 126.2 crore, down 13% YoY (Page 8) - Revenue ex-real estate: INR 124.3 crore, down 12% YoY (Page 5) - Nutrition business: - Vitamin D3 – Human Nutrition: INR 76.5 cro EBITDA: INR 22.4 crore in Q1FY27, down 39% YoY; INR 22.3 crore ex-real estate, down 37% YoY (Page 5) - Profit After Tax (PAT): INR 9.5 crore in Q1FY27, down 56% YoY (Page 5 and Page 8) - Year-on-Year Change: EBITDA down 39% YoY, PAT down 56% YoY (Page 5)
From Fermenta Biotech Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1FY27 total revenue: INR 126.2 crore, down 13% YoY (Page 8)
- Revenue ex-real estate: INR 124.3 crore, down 12% YoY (Page 5)
- Nutrition business:
- Vitamin D3 – Human Nutrition: INR 76.5 crore, down 10% YoY but up 24% QoQ (Page 7)
- Vitamin D3 – Animal Nutrition: INR 12.6 crore, down 41% YoY and 45% QoQ (Page 7)
- Others (Nutrition): INR 11.0 crore, up 28% YoY and 16% QoQ (Page 7)
- Other APIs and Intermediates: INR 11.6 crore, up 18% YoY (Page 7)
- Green Chemistry Solutions / Enzymes: INR 2.3 crore, up 15% YoY (Page 7)
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- ₹110 crore capex at Dahej for capacity committed to Spray-Dried Vitamin D3 Calcifediol scale-up (Page 16).
- Dahej plant referenced for integrated, advanced manufacturing scale alongside Kullu and Tirupati (Page 12, 11).
- Capacity scale-up at Dahej mentioned as a reason for increased employee costs ahead of the ramp-up (Page 9).
- Launch readiness for Spray-Dried Vitamin D3 Calcifediol is approaching final validation as clinical demand opens (Page 16).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 122 | 136 | -10.6% | 122 | +0.2% |
| Operating profit (EBITDA) | 18 | 28 | -36% | 20 | -9.7% |
| Operating margin | 14.83% | 20.73% | -5.9 pp | 16.45% | -1.6 pp |
| Profit before tax | 15 | 28 | -47.7% | 26 | -44% |
| Net profit (PAT) | 10 | 22 | -55.9% | 19 | -48.8% |
| EPS (₹) | 3.31 | 7.42 | -55.4% | 6.52 | -49.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q1 FY27 results?
Q1FY27 total revenue: INR 126.2 crore, down 13% YoY (Page 8) - Revenue ex-real estate: INR 124.3 crore, down 12% YoY (Page 5) - Nutrition business: - Vitamin D3 – Human Nutrition: INR 76.5 cro EBITDA: INR 22.4 crore in Q1FY27, down 39% YoY; INR 22.3 crore ex-real estate, down 37% YoY (Page 5) - Profit After Tax (PAT): INR 9.5 crore in Q1FY27, down 56% YoY (Page 5 and Page 8) - Year-on-Year Change: EBITDA down 39% YoY, PAT down 56% YoY (Page 5)
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
₹110 crore capex at Dahej for capacity committed to Spray-Dried Vitamin D3 Calcifediol scale-up (Page 16).
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
